Hologic, Inc. (NASDAQ:HOLX) Given Average Rating of “Hold” by Brokerages

Shares of Hologic, Inc. (NASDAQ:HOLX) have received an average recommendation of “Hold” from the fifteen analysts that are currently covering the stock, Marketbeat.com reports. Thirteen research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $78.4167.

Several research analysts have commented on HOLX shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hologic in a research note on Wednesday, January 28th. BNP Paribas Exane downgraded shares of Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 target price on the stock. in a research note on Friday, November 21st. Argus lowered shares of Hologic from a “buy” rating to a “hold” rating in a report on Monday, January 12th. Finally, Evercore cut shares of Hologic from an “outperform” rating to an “in-line” rating and dropped their price target for the stock from $79.00 to $78.00 in a research note on Monday, January 5th.

Hologic Trading Up 0.0%

Shares of NASDAQ HOLX opened at $75.15 on Tuesday. Hologic has a 1-year low of $51.90 and a 1-year high of $75.75. The company has a debt-to-equity ratio of 0.48, a current ratio of 4.04 and a quick ratio of 3.32. The business’s 50 day moving average is $75.14 and its two-hundred day moving average is $72.78. The stock has a market capitalization of $16.78 billion, a P/E ratio of 31.31, a PEG ratio of 2.24 and a beta of 0.73.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.09 by ($0.05). The company had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.07 billion. Hologic had a net margin of 13.18% and a return on equity of 19.58%. Hologic’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.87 earnings per share. As a group, research analysts expect that Hologic will post 4.28 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Invesco Ltd. grew its holdings in shares of Hologic by 72.5% in the second quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock worth $543,486,000 after purchasing an additional 3,505,828 shares during the last quarter. Becker Capital Management Inc. increased its stake in Hologic by 20.0% in the 3rd quarter. Becker Capital Management Inc. now owns 81,755 shares of the medical equipment provider’s stock worth $5,518,000 after buying an additional 13,610 shares during the period. Natixis Advisors LLC lifted its holdings in Hologic by 23.4% during the 3rd quarter. Natixis Advisors LLC now owns 437,338 shares of the medical equipment provider’s stock valued at $29,516,000 after buying an additional 82,894 shares in the last quarter. Illinois Municipal Retirement Fund boosted its position in Hologic by 20.4% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 172,294 shares of the medical equipment provider’s stock valued at $11,628,000 after buying an additional 29,143 shares during the period. Finally, Readystate Asset Management LP purchased a new stake in Hologic in the 3rd quarter valued at about $4,161,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.